NASH is a severe form of
non-alcoholic fatty liver disease (NAFLD) characterised by liver cell (hepatocyte) damage, liver inflammation and fibrosis that can progress to cirrhosis, liver failure, cancer and death.
Non-alcoholic fatty liver disease. In: Feldman M, Frieddman LS, Brandt LJ, eds.
[USA], Jun 8 (ANI): In a major relief to paediatric
Non-Alcoholic Fatty Liver Disease (NAFLD) patients, a new blood test could become clinical practice within five years, reducing the need for a liver biopsy in the patients.
Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of people in the West and is the most common cause of liver disease around the world.
Dr Jameel Ahmed, Professor of medicine at the Baqai Medical University, spoke on
non-alcoholic fatty liver disease and informed that weight loss through exercise, diet control and living an active life could prevent people from fatty liver disease, which later converted into chronic liver disease and other fatal complications.
The
non-alcoholic fatty liver disease activity score, the clinical measure of NASH activity, improved in the majority of animals treated with the combination of larazotide/OCA when compared to vehicle.
Promethera is pioneering the use of liver-derived stem cells for the treatment of ACLF and
non-alcoholic fatty liver disease (NASH).
On the other hand,
non-alcoholic fatty liver disease (NA-FLD) as a subclass of fatty liver disease has become one of the major public health problems as it increases the risk of liver cirrhosis, liver cancer, and metabolic disorders and is regarded as a metabolic syndrome (MetS) exhibited by the liver (1).
Summary:
Non-alcoholic fatty liver disease causing increasing liver damage among UAE residents
The result is an epidemic crisis of
non-alcoholic fatty liver disease (NAFLD).
Abdominal obesity is a criteria of the metabolic syndrome, also called pre-diabetes, which is a cluster of abnormalities characterized by insulin resistance, inflammation, oxidative stress, hypertension and dyslipidaemia which carries increased risk of type 2 diabetes mellitus(T2DM), cardiovascular disease,
non-alcoholic fatty liver disease (NAFLD) and cancer (Kopelman, 2000; Eckel et al, 2005; Grattagliano et al., 2008).
Systematic review: the epidemiology and natural history of
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.